UNLABELLED: Auger electron emitters such as (125)I have a high linear energy transfer and short range of emission (<10 μm), making them suitable for treating micrometastases while sparing normal tissues. We used a highly specific small molecule targeting the prostate-specific membrane antigen (PSMA) to deliver (125)I to prostate cancer cells. METHODS: The PSMA-targeting Auger emitter 2-[3-[1-carboxy-5-(4-(125)I-iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid ((125)I-DCIBzL) was synthesized. DNA damage (via phosphorylated H2A histone family member X staining) and clonogenic survival were tested in PSMA-positive (PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human prostate cancer cells after treatment with (125)I-DCIBzL. Subcellular drug distribution was assessed with confocal microscopy using a related fluorescent PSMA-targeting compound YC-36. In vivo antitumor efficacy was tested in nude mice bearing PSMA+ PC3 PIP or PSMA- PC3 flu flank xenografts. Animals were administered (intravenously) 111 MBq (3 mCi) of (125)I-DCIBzL, 111 MBq (3 mCi) of (125)I-NaI, an equivalent amount of nonradiolabeled DCIBzL, or saline. RESULTS: After treatment with (125)I-DCIBzL, PSMA+ PC3 PIP cells exhibited increased DNA damage and decreased clonogenic survival when compared with PSMA- PC3 flu cells. Confocal microscopy of YC-36 showed drug distribution in the perinuclear area and plasma membrane. Animals bearing PSMA+ PC3 PIP tumors had significant tumor growth delay after treatment with (125)I-DCIBzL, with only 1 mouse reaching 5 times the initial tumor volume by 60 d after treatment, compared with a median time to 5 times volume of less than 15 d for PSMA- PC3 flu tumors and all other treatment groups (P = 0.002 by log-rank test). CONCLUSION: PSMA-targeted radiopharmaceutical therapy with the Auger emitter (125)I-DCIBzL yielded highly specific antitumor efficacy in vivo, suggesting promise for treatment of prostate cancer micrometastases.
UNLABELLED: Auger electron emitters such as (125)I have a high linear energy transfer and short range of emission (<10 μm), making them suitable for treating micrometastases while sparing normal tissues. We used a highly specific small molecule targeting the prostate-specific membrane antigen (PSMA) to deliver (125)I to prostate cancer cells. METHODS: The PSMA-targeting Auger emitter 2-[3-[1-carboxy-5-(4-(125)I-iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid ((125)I-DCIBzL) was synthesized. DNA damage (via phosphorylated H2A histone family member X staining) and clonogenic survival were tested in PSMA-positive (PSMA+) PC3PIP and PSMA-negative (PSMA-) PC3 flu humanprostate cancer cells after treatment with (125)I-DCIBzL. Subcellular drug distribution was assessed with confocal microscopy using a related fluorescent PSMA-targeting compound YC-36. In vivo antitumor efficacy was tested in nude mice bearing PSMA+ PC3PIP or PSMA-PC3 flu flank xenografts. Animals were administered (intravenously) 111 MBq (3 mCi) of (125)I-DCIBzL, 111 MBq (3 mCi) of (125)I-NaI, an equivalent amount of nonradiolabeled DCIBzL, or saline. RESULTS: After treatment with (125)I-DCIBzL, PSMA+ PC3PIP cells exhibited increased DNA damage and decreased clonogenic survival when compared with PSMA-PC3 flu cells. Confocal microscopy of YC-36 showed drug distribution in the perinuclear area and plasma membrane. Animals bearing PSMA+ PC3PIP tumors had significant tumor growth delay after treatment with (125)I-DCIBzL, with only 1 mouse reaching 5 times the initial tumor volume by 60 d after treatment, compared with a median time to 5 times volume of less than 15 d for PSMA-PC3flu tumors and all other treatment groups (P = 0.002 by log-rank test). CONCLUSION: PSMA-targeted radiopharmaceutical therapy with the Auger emitter (125)I-DCIBzL yielded highly specific antitumor efficacy in vivo, suggesting promise for treatment of prostate cancer micrometastases.
Authors: S V Govindan; D M Goldenberg; S E Elsamra; G L Griffiths; G L Ong; M W Brechbiel; J Burton; G Sgouros; M J Mattes Journal: J Nucl Med Date: 2000-12 Impact factor: 10.057
Authors: Gopalakrishnapillai Anilkumar; Sigrid A Rajasekaran; Song Wang; Oliver Hankinson; Neil H Bander; Ayyappan K Rajasekaran Journal: Cancer Res Date: 2003-05-15 Impact factor: 12.701
Authors: Sangeeta R Banerjee; Catherine A Foss; Allen Horhota; Mrudula Pullambhatla; Kevin McDonnell; Stephen Zale; Martin G Pomper Journal: Biomacromolecules Date: 2016-12-21 Impact factor: 6.988
Authors: Ana P Kiess; Il Minn; Ganesan Vaidyanathan; Robert F Hobbs; Anders Josefsson; Colette Shen; Mary Brummet; Ying Chen; Jaeyeon Choi; Eftychia Koumarianou; Kwamena Baidoo; Martin W Brechbiel; Ronnie C Mease; George Sgouros; Michael R Zalutsky; Martin G Pomper Journal: J Nucl Med Date: 2016-05-26 Impact factor: 10.057
Authors: Sangeeta Ray Banerjee; Vivek Kumar; Ala Lisok; Jian Chen; Il Minn; Mary Brummet; Srikanth Boinapally; Michael Cole; Ethel Ngen; Bryan Wharram; Cory Brayton; Robert F Hobbs; Martin G Pomper Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-10 Impact factor: 9.236
Authors: Steven P Rowe; Alexander Drzezga; Bernd Neumaier; Markus Dietlein; Michael A Gorin; Michael R Zalutsky; Martin G Pomper Journal: J Nucl Med Date: 2016-10 Impact factor: 10.057
Authors: Giacomo Pirovano; Stephen A Jannetti; Lukas M Carter; Ahmad Sadique; Susanne Kossatz; Navjot Guru; Paula Demétrio De Souza França; Masatomo Maeda; Brian M Zeglis; Jason S Lewis; John L Humm; Thomas Reiner Journal: Clin Cancer Res Date: 2020-02-17 Impact factor: 12.531
Authors: Kara M Harmatys; Marta Overchuk; Juan Chen; Lili Ding; Ying Chen; Martin G Pomper; Gang Zheng Journal: Bioconjug Chem Date: 2018-10-29 Impact factor: 4.774
Authors: Vincenzo Abbate; Samantha Y A Terry; Katarzyna M Osytek; Philip J Blower; Ines M Costa; Gareth E Smith Journal: EJNMMI Res Date: 2021-07-05 Impact factor: 3.138